Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

YouTube Videos: Opportunities And Risks For Device Firms

This article was originally published in The Gray Sheet

Executive Summary

Device-makers that have been reluctant to add product videos to YouTube might need to produce them anyway to counteract inaccurate or even dangerous user videos, one consultant says – but the step isn’t totally without risk. For example, attorney Colleen Heisey questions whether creating online video is the best use of a company’s limited resources: “You have to go viral to have the impact of millions of viewers … so you’re coming up with a digital engagement strategy, and the effort to do that might be better placed elsewhere."

You may also be interested in...



Critics Call FDA Third-Party Social Media Guidance ‘Overbroad’

Some stakeholders are concerned the agency’s draft guidance is overreaching and could have a chilling effect. AdvaMed recommends FDA consider splitting the guidance into product-specific documents to reference regulations that may apply to industries differently.

FDA Twitter Guidance Lacks Flexibility, And May Be Unconstitutional, Critics Say

Stakeholders say the agency’s communication requirements for space-limited online platforms are too restricting and violate the First Amendment. Many of them are calling on the agency to withdraw the guidance and try again. The device industry has a comparatively toned down response so far, but wants more flexibility.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Topics

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel